Leading healthcare company MSD has just announced that it will create 200 new jobs across three of its Irish manufacturing sites by the end of 2016.
Due to continued growth and an increase in the supply of products to the global market from Ireland, MSD is recruiting experienced professionals for positions based at MSD’s locations in Carlow, Cork and Tipperary. The new roles span Operations, Quality, Engineering, Supply Chain, and Commercial Operations.
Ger Carmody, Associate Vice President, and Site Lead at MSD in Ballydine, Tipperary, said: “Today’s announcement reflects the critical role MSD’s Irish sites play in our wider global manufacturing network. Those taking up these new roles will be at the cutting edge of healthcare innovation and will play a key role in delivering MSD’s overall ambition to preserve and improve human life. Our state-of-the-art facilities in Carlow, Cork and Tipperary are leading the way in the development of new medicines, including MSD’s new treatments for cancer and hepatitis C, which are being manufactured in Ireland for the world market. Today, our Irish sites are involved in the production of over 60% of MSD’s global top 20 products.”
MSD in Carlow, the company’s only standalone vaccine and biologics facility outside the US, is creating 110 new roles spanning production, engineering and quality control. MSD in Brinny, Co. Cork, which specialises in the fermentation and sterile filling of biotech products, is seeking 50 new hires in manufacturing, quality, technology, engineering and environmental & safety. Finally, MSD in Ballydine, Co. Tipperary, which is involved in the R&D, formulation and manufacture of active pharmaceutical ingredients, will recruit 40 new employees, including process and chemical engineers and organic chemists by year end.
Recognised as Ireland’s Pharma Company and Biopharma Company of the Year in 2015, MSD already employs over 2,000 people across five sites in Ireland – in Dublin, Carlow, Cork, Tipperary and Wicklow. Its extensive Irish operations, encompassing manufacturing, commercial, global financial services and marketing facilities, had a turnover of €3 billion in 2014. MSD has a strong legacy in Ireland that stretches back over the last 50 years, and in that time, the company has invested over $2.5 billion in expanding and developing its facilities here. The company provides healthcare solutions and innovative medicines in areas such as diabetes, heart disease, immunology, oncology, infectious diseases, women’s health and anaesthesia.